KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Takeda Pharmaceutical (TAK) Interest Expenses (2025)

Takeda Pharmaceutical has reported Interest Expenses over the past 1 years, most recently at -$324.9 million for Q4 2025.

  • For Q4 2025, Interest Expenses changed N/A year-over-year to -$324.9 million; the TTM value through Mar 2026 reached -$324.9 million, changed N/A, while the annual FY2026 figure was -$2.4 billion, 72.25% down from the prior year.
  • Interest Expenses was -$324.9 million for Q4 2025 at Takeda Pharmaceutical.
  • Across five years, Interest Expenses topped out at -$324.9 million in Q4 2025 and bottomed at -$324.9 million in Q4 2025.